Marc Cummings, president and CEO of Life Science Washington, stresses that the life sciences industry values regulation to ensure the trustworthiness of new drugs.
While industries outside biotech may show frustration with regulation, “the life sciences really welcomes it,” said Cummings. “In order to have a drug in the market that people trust, it’s well worth doing.”
Despite concerns over federal policy changes, Washington’s biotech sector continues to thrive, with Life Science Washington driving progress by championing policies and fostering collaboration.